Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Vtv Theraptcs Cl A

(NASDAQ: VTVT)
Add to Portfolio
-0.02 (-1.40%)
as of 15:59 EDT

Last 1.41
Change -0.02 (-1.40%)
Open 1.44
Prev. Close 1.43
Today's Range
1.41
1.46
52wk Range
1.00
4.59
Volume 100,223
Avg Volume 221,348
Sector SIC-2834 Pharmaceutical Preparations

Perfomance Comparison

Name Today 3-Month 1-Year
VTVT -1.40% +9.30% -50.18%
DJIA -0.08% +3.74% +4.68%
S&P 500 -0.20% +3.74% +6.39%

Key Statistics

Annual EPS -0.52
Dividend Yield 0.00%
P/E Ratio N/A
Market Capitalization, $K 76,870
Weighted Alpha -58.40
Standard Deviation -0.20
Profit Margin N/A
Beta -3.61

Growth Rates

YTD -46.79%
1-Year -61.76%
3-Year -79.00%

Opinion

Sell Hold Buy

Recent Headlines

vTv to Host Key Opinion Leader Event to Discuss the

GlobeNewswire via COMTEX - Thu Oct 03, 07:30AM EDT
vTv Therapeutics Inc. (Nasdaq: VTVT), today announced that the Company will host a key opinion leader (KOL) presentation and webcast discussing the type 1 diabetes (T1D) treatment landscape and emerging therapies in New York City (full story)
VTVT: 1.41 (-0.02)

6 Small Drug Stocks in Focus Ahead of World

ZACKS - Fri Sep 20, 10:02AM EDT
Here we discuss six small-cap companies with promising candidates in their pipeline for Alzheimer's disease.(full story)
ITCI: 8.40 (+0.17), VTVT: 1.41 (-0.02), INMB: 3.76 (+0.20), ACIU: 4.85 (-0.06), ALEC: 14.89 (+0.18), SAVA: 1.24 (-0.03)

vTv Therapeutics Presents Additional Positive Data

GlobeNewswire via COMTEX - Wed Sep 18, 07:30AM EDT
vTv Therapeutics Inc. (Nasdaq: VTVT), today presented additional positive data from its phase 2 Simplici-T1 study in patients with type 1 diabetes (T1D) at the 55th Annual Meeting of the European Association for the Study of Diabe(full story)
VTVT: 1.41 (-0.02)

vTv Therapeutics to Present Posters at Two Scientific

GlobeNewswire via COMTEX - Wed Sep 11, 07:30AM EDT
Presenting New Clinical Data from Phase 2 Study in Type 1 Diabetes with Liver Selective GKA Program(full story)
VTVT: 1.41 (-0.02)

vTv Therapeutics to Present at the H.C. Wainwright

GlobeNewswire via COMTEX - Wed Sep 04, 07:30AM EDT
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for diabetes and Alzheimer's disease, today announced that it is scheduled to present a (full story)
VTVT: 1.41 (-0.02)